美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Kailera Therapeutics, Inc.

26.00

+10.0062.50%

盘后：25.40-0.6000-2.31%19:59 EDT

成交量：811.43万

成交额：2.08亿

市值：30.67亿

市盈率：- -

高：27.50

开：26.00

低：23.70

收：16.00

52周最高：27.50

52周最低：23.70

股本：1.18亿

流通股本：3,333.33万

量比：- -

换手率：24.34%

股息：- -

股息率：- -

净资产收益率：-36.90%

总资产收益率：-22.73%

市净率：-8.60

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

Kailera Therapeutics, Inc.

交易所：

NASDAQ

成立时间：

2024

员工人数：

145

公司地址：

180 Third Avenue,4th Floor,Waltham,Massachusetts,United States

官网：

http://www.kailera.com

邮编：

02451

电话：

传真：

- -

简介：

Kailera Therapeutics, Inc.于2024年5月8日根据特拉华州法律注册成立。该公司是一家处于临床阶段的生物技术公司，致力于通过推进多元化的研发管线，引领肥胖症治疗的新时代。目前，该公司正在快速推进四款处于临床阶段的候选产品，这些产品利用多种基于胰高血糖素样肽-1 (GLP-1) 的作用机制和给药途径。

董事

名称

职位

John F. Milligan

Chairman

Ronald C. Renaud, Jr.

President, Chief Executive Officer and Director

Adam Koppel

Director

Amir Zamani

Director

Andrew Kaplan

Director

Christopher Hite

Director

Frank Clyburn, Jr.

Director

Martin Mackay

Director

Michael Gladstone

Director

Yuting Liu

Director

股东

名称

职位

Ronald C. Renaud, Jr.

President, Chief Executive Officer and Director

Paul Burgess

Chief Operating Officer and Chief Business Officer

Douglas Pagán

Chief Financial Officer

Jamie Coleman

Chief Commercial Officer

Paula Cloghessy

Chief People Officer

Scott Akamine

Chief Legal Officer and Secretary

Scott Wasserman

Chief Medical Officer

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/KLRA/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KLRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRA\",,,,,undefined,":{"symbol":"KLRA","market":"US","secType":"STK","nameCN":"Kailera Therapeutics, Inc.","latestPrice":26,"timestamp":1776456000000,"preClose":16,"halted":0,"volume":8114314,"hourTrading":{"tag":"盘后","latestPrice":25.4,"preClose":26,"latestTime":"19:59 EDT","volume":38738,"amount":996352.9387,"timestamp":1776470387477,"change":-0.6,"changeRate":-0.023077,"amplitude":0.047308},"delay":0,"changeRate":0.625,"floatShares":33333334,"shares":117948773,"eps":0,"marketStatus":"未开盘","change":10,"latestTime":"04-17 16:00:00 EDT","open":26,"high":27.5,"low":23.7,"amount":208032997.18292,"amplitude":0.2375,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1776672000000},"marketStatusCode":0,"adr":0,"listingDate":1776398400000,"exchange":"NASDAQ","adjPreClose":16,"postHourTrading":{"tag":"盘后","latestPrice":25.4,"preClose":26,"latestTime":"19:59 EDT","volume":38738,"amount":996352.9387,"timestamp":1776470387477,"change":-0.6,"changeRate":-0.023077,"amplitude":0.047308},"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRA\",,,,,undefined,":{"symbol":"KLRA","floatShares":33333334,"roa":"-22.73%","roe":"-36.90%","lyrEps":0,"shares":117948773,"dividePrice":0,"high":27.5,"amplitude":0.2375,"preClose":16,"low":23.7,"week52Low":23.7,"pbRate":"-8.60","week52High":27.5,"institutionHeld":0,"latestPrice":26,"eps":0,"divideRate":0,"volume":8114314,"delay":0,"ttmEps":0,"open":26,"prevYearClose":16,"prevWeekClose":16,"prevMonthClose":16,"prevQuarterClose":16,"fiveDayClose":16,"twentyDayClose":16,"sixtyDayClose":16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KLRA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KLRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KLRA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KLRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KLRA","date":"2026-04-17","current":-12.669466,"percent":0,"low":-12.669466,"twenty":-12.511098,"median":-12.273546,"eighty":-12.035993,"high":-11.877625,"avg":-12.273546,"sd":0.39592,"marketCap":1887180368},"quantilePoints":[{"date":"2026-04-17","current":-12.669466,"twenty":-12.511098,"median":-12.273546,"eighty":-12.035993,"marketCap":1887180368}],"updateTime":1776662546561},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1899116257,"yearFounded":2024,"employeeNum":145,"address":"180 Third Avenue,4th Floor,Waltham,Massachusetts,United States","zipCode":"02451","officePhone":"(781) 317-0290","fiscalYearEnd":"12-31"},"stockCompanyDetail":{"websiteUrl":"http://www.kailera.com","stockEarnings":[{"period":"1week","weight":0.625},{"period":"ytd","weight":0.625}],"compareEarnings":[{"period":"1week","weight":0.0452},{"period":"1month","weight":0.0736},{"period":"3month","weight":0.0267},{"period":"6month","weight":0.0689},{"period":"1year","weight":0.349},{"period":"ytd","weight":0.0414}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Kailera Therapeutics, Inc.于2024年5月8日根据特拉华州法律注册成立。该公司是一家处于临床阶段的生物技术公司，致力于通过推进多元化的研发管线，引领肥胖症治疗的新时代。目前，该公司正在快速推进四款处于临床阶段的候选产品，这些产品利用多种基于胰高血糖素样肽-1 (GLP-1) 的作用机制和给药途径。","exchange":"NASDAQ","name":"Kailera Therapeutics, Inc.","nameEN":"Kailera Therapeutics"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"KLRA\",market:\"US\",,,undefined,":{"directors":[{"name":"John F. Milligan","position":"Chairman"},{"name":"Ronald C. Renaud, Jr.","position":"President, Chief Executive Officer and Director"},{"name":"Adam Koppel","position":"Director"},{"name":"Amir Zamani","position":"Director"},{"name":"Andrew Kaplan","position":"Director"},{"name":"Christopher Hite","position":"Director"},{"name":"Frank Clyburn, Jr.","position":"Director"},{"name":"Martin Mackay","position":"Director"},{"name":"Michael Gladstone","position":"Director"},{"name":"Yuting Liu","position":"Director"}],"executives":[{"name":"Ronald C. Renaud, Jr.","position":"President, Chief Executive Officer and Director"},{"name":"Paul Burgess","position":"Chief Operating Officer and Chief Business Officer"},{"name":"Douglas Pagán","position":"Chief Financial Officer"},{"name":"Jamie Coleman","position":"Chief Commercial Officer"},{"name":"Paula Cloghessy","position":"Chief People Officer"},{"name":"Scott Akamine","position":"Chief Legal Officer and Secretary"},{"name":"Scott Wasserman","position":"Chief Medical Officer"}]}}}